Research
Hormonal
GLP-1 receptor agonists provide cardiovascular protection by reducing major adverse cardiac events (MACE), independent of substantial glucose lowering, through mechanisms including improved endothelial function and reduced inflammation.
GLP-1 medications offer significant cardiovascular protection, reducing the risk of heart attack, stroke, and cardiovascular death. This benefit exists even in non-diabetic obese patients, likely due to improved blood vessel function and reduced inflammation, not just weight loss or blood sugar control.
StrongSupportsVERY_HIGH confidence
This result suggests that semaglutide has cardioprotective effect independent of any substantial glucose lowering properties. These include not only effects of weight loss, but also improvements in endothelial function, reductions in low-grade inflammation (evidenced by a significant decrease in high-sensitivity C-reactive protein levels), and potential plaque stabilization [73].
Why this rating
Supported by multiple large-scale clinical trials (LEADER, SUSTAIN-6, SELECT) and meta-analyses.
Source
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Jang Won Son et al. · Endocrinology and Metabolism · 2024
narrative_reviewCited 20×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →